<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58140">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349152</url>
  </required_header>
  <id_info>
    <org_study_id>PRO14110258</org_study_id>
    <nct_id>NCT02349152</nct_id>
  </id_info>
  <brief_title>Remifentanil and Glycemic Response in Cardiac Surgery</brief_title>
  <official_title>The Effect of Intraoperative Continuous Remifentanil Infusion on Glycemic Response and Variability in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Prospective, Randomized, Open Label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of using remifentanil during cardiopulmonary bypass surgery
      to supress the hyperglycemic response in perioperative period. Half of the participants will
      receive continuous intravenous remifentanil during surgery, while the other half will
      receive intermittent intravenous fentanyl during surgery. Intermittent intravenous fentanyl
      administration is this institution's standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stress-induced hyperglycemia is a well-known phenomena that occurs during cardiopulmonary
      bypass surgery. Hyperglycemia increases the incidence of major adverse events and mortality
      in patients undergoing cardiac surgery.

      Remifentanil, an ultra-short acting opioid analgesic, has been shown to reduce the stress
      response to cardiopulmonary bypass when compared to intermittent fentanyl and inhalation
      anesthesia. This in turn, will reduce the occurence of perioperative hyperglycemia, glycemic
      variability and insulin requirements in patients undergoing cardiac surgery.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Glucose Levels</measure>
    <time_frame>Every hour from induction of anesthesia to 24 hours postoperatively</time_frame>
    <description>Peak glucose levels, Average Glucose levels intraoperatively and postoperatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>Every hour from induction of anesthesia to 24 hours postoperatively</time_frame>
    <description>Glycemic variability calculated for each group as coefficient of variation from blood glucose levels taken every hour for 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin requirement</measure>
    <time_frame>Starting from induction of anesthesia to 24 hours postoperatively</time_frame>
    <description>Starting from induction of anesthesia to 24 hours postoperatively, Insulin management based on institutional glucose management protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative Pre-cardiopulmonary bypass hemodynamic stability</measure>
    <time_frame>intraoperative</time_frame>
    <description>Blood pressure (systolic, diastolic and mean), Heart rate every 5 minutes from induction of anesthesia till systemic heparinization before cardiopulmonary bypass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence from anesthesia</measure>
    <time_frame>Immediate postoperative period (24 hours postoperative hours)</time_frame>
    <description>Time to wake up, time to extubation after completion of surgery in the operating room and intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress hormone and inflammatory mediator levels</measure>
    <time_frame>Perioperative period (Intraoperatively and 6 hours postoperatively)</time_frame>
    <description>Prebypass, cardiopulmonary bypass (2 samples), postbypass, ICU 6 hours postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Every hour for 48 hours postoperative period</time_frame>
    <description>Visual analog scale for pain assessment &amp; Total analgesic requirement (Morphine, oxycodone and tylenol used as analgesics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound hyperalgesia</measure>
    <time_frame>48 hours postoperatively and at Postoperative day seven</time_frame>
    <description>Von frey hair objective testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of chronic pain</measure>
    <time_frame>1, 3, 6 and 12 months after discharge from the hospital</time_frame>
    <description>Telephonic call Numeric pain scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Heart Diseases</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Remifentanil group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of subjects enrolled will be randomized to the remifentanil group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of subjects enrolled will be randomized to the fentanyl group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Subjects in the experimental group will receive remifentanil infusion 0.2-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.</description>
    <arm_group_label>Remifentanil group</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.</description>
    <arm_group_label>Fentanyl group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Open cardiac surgery through sternotomy approach (coronary artery bypass, valve
             surgery, and any other open heart surgeries)

          -  Surgery with use of cardiopulmonary bypass

          -  Patients over 18 years of age

          -  Both female and male genders

          -  All races

        Exclusion Criteria:

          -  Minimally invasive heart surgery through thoracotomy approach

          -  Patients receiving regional analgesia such as intrathecal morphine

          -  Patients undergoing procedures under deep hypothermic circulatory arrest

          -  Patients with active infections such as acute infective endocarditis

          -  Emergency surgery

          -  Patients undergoing transplantations and ventricular assist device insertion

          -  Patients on any mechanical circulatory support preoperatively

          -  Patient's refusal

          -  Allergy to remifentanil

          -  Positive pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathrivel Subramaniam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V, Borger MA. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2005 Oct;130(4):1144.</citation>
    <PMID>16214532</PMID>
  </results_reference>
  <results_reference>
    <citation>Ihn CH, Joo JD, Choi JW, Kim DW, Jeon YS, Kim YS, Jung HS, Kwon SY. Comparison of stress hormone response, interleukin-6 and anaesthetic characteristics of two anaesthetic techniques: volatile induction and maintenance of anaesthesia using sevoflurane versus total intravenous anaesthesia using propofol and remifentanil. J Int Med Res. 2009 Nov-Dec;37(6):1760-71.</citation>
    <PMID>20146874</PMID>
  </results_reference>
  <results_reference>
    <citation>Subramaniam B, Lerner A, Novack V, Khabbaz K, Paryente-Wiesmann M, Hess P, Talmor D. Increased glycemic variability in patients with elevated preoperative HbA1C predicts adverse outcomes following coronary artery bypass grafting surgery. Anesth Analg. 2014 Feb;118(2):277-87. doi: 10.1213/ANE.0000000000000100.</citation>
    <PMID>24445629</PMID>
  </results_reference>
  <results_reference>
    <citation>Shinoda T, Murakami W, Takamichi Y, Iizuka H, Tanaka M, Kuwasako Y. Effect of remifentanil infusion rate on stress response in orthopedic surgery using a tourniquet application. BMC Anesthesiol. 2013 Jul 10;13:14. doi: 10.1186/1471-2253-13-14. eCollection 2013 Jul 10.</citation>
    <PMID>23837943</PMID>
  </results_reference>
  <results_reference>
    <citation>Cok OY, Ozkose Z, Pasaoglu H, Yardim S. Glucose response during craniotomy: propofol-remifentanil versus isoflurane-remifentanil. Minerva Anestesiol. 2011 Dec;77(12):1141-8. Epub 2011 May 20.</citation>
    <PMID>21602751</PMID>
  </results_reference>
  <results_reference>
    <citation>Lazar HL, McDonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR, Bridges CR, Haan CK, Svedjeholm R, Taegtmeyer H, Shemin RJ; Society of Thoracic Surgeons Blood Glucose Guideline Task Force.. The Society of Thoracic Surgeons practice guideline series: Blood glucose management during adult cardiac surgery. Ann Thorac Surg. 2009 Feb;87(2):663-9. doi: 10.1016/j.athoracsur.2008.11.011. Review.</citation>
    <PMID>19161815</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>January 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Kathirvel Subramaniam</investigator_full_name>
    <investigator_title>Visiting Associate Professor in Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Cardiopulmonary bypass</keyword>
  <keyword>Heart surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
